MCID: HLL004
MIFTS: 51

Hellp Syndrome

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hellp Syndrome

MalaCards integrated aliases for Hellp Syndrome:

Name: Hellp Syndrome 12 76 53 59 55 44 15 73
Hemolysis, Elevated Liver Enzymes, Low Platelets in Pregnancy 59
Hemolysis-Elevated Liver Enzymes-Low Platelets Syndrome 59
Hemolysis, Elevated Liver Enzymes, Lowered Platelets 53

Classifications:



External Ids:

Disease Ontology 12 DOID:13133
ICD10 33 O14.2
MeSH 44 D017359
NCIt 50 C84750
SNOMED-CT 68 95605009
Orphanet 59 ORPHA244242
MESH via Orphanet 45 D017359
UMLS via Orphanet 74 C0162739
ICD10 via Orphanet 34 O14.2
UMLS 73 C0162739

Summaries for Hellp Syndrome

NIH Rare Diseases : 53 HELLP syndrome is a life-threatening condition that can potentially complicate pregnancy. It is named for 3 features of the condition: Hemolysis, Elevated Liver enzyme levels, and Low Platelet levels. It typically occurs in the last 3 months of pregnancy (the third trimester) but can also start soon after delivery. A wide range of non-specific symptoms may be present in women with HELLP syndrome. Symptoms may include fatigue; malaise; fluid retention and excess weight gain; headache; nausea and vomiting; pain in the upper right or middle of the abdomen; blurry vision; and rarely, nosebleed or seizures. The cause of HELLP syndrome is not known, but certain risk factors have been associated with the condition. It is most common in women with preeclampsia or eclampsia. If not diagnosed and treated quickly, HELLP syndrome can lead to serious complications for the mother and baby. The main treatment is to deliver the baby as soon as possible, even if premature, if there is distress of the mother or the baby. Treatment may also include medications needed for the mother or baby, and blood transfusion for severe bleeding problems.

MalaCards based summary : Hellp Syndrome, also known as hemolysis, elevated liver enzymes, low platelets in pregnancy, is related to eclampsia and pre-eclampsia. An important gene associated with Hellp Syndrome is HELLPAR (HELLP Associated Long Non-Coding RNA), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A severe pre-eclampsia characterized by hemolysis, elevated liver enzyme and low platelet count.

Wikipedia : 76 HELLP syndrome is a complication of pregnancy characterized by hemolysis, elevated liver enzymes, and a... more...

Related Diseases for Hellp Syndrome

Diseases related to Hellp Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
# Related Disease Score Top Affiliating Genes
1 eclampsia 31.0 F2 FLT1 LGALS13 MTHFR PGF SERPINC1
2 pre-eclampsia 30.8 APOH F2 F5 FLT1 HADHA LGALS13
3 severe pre-eclampsia 30.7 APOH F5 LGALS13 PGF SERPINC1
4 hepatic infarction 30.5 APOH F2 HADHA MTHFR SERPINC1
5 antiphospholipid syndrome 30.4 ADAMTS13 APOH F2 F5 MTHFR SERPINC1
6 cholecystitis 30.4 F2 GPT HP
7 purpura 30.3 ADAMTS13 APOH F2 SERPINC1 VWF
8 disseminated intravascular coagulation 30.1 ADAMTS13 F2 F5 SERPINC1 SERPINE1
9 nonarteritic anterior ischemic optic neuropathy 30.0 F2 F5 MTHFR SERPINC1
10 hemolytic anemia 29.9 ADAMTS13 CFH CFI HP
11 thrombotic thrombocytopenic purpura 29.9 ADAMTS13 APOH CD46 CFH VWF
12 placental insufficiency 29.9 F2 FLT1 PGF
13 central retinal vein occlusion 29.9 APOH F2 F5 MTHFR SERPINC1
14 ischemic optic neuropathy 29.9 APOH F2 F5 MTHFR SERPINC1
15 coronary artery anomaly 29.8 F2 F5 HP SERPINE1
16 thrombophilia 29.8 APOH F2 F5 MTHFR SERPINC1 SERPINE1
17 thrombosis 29.7 ADAMTS13 APOH F2 F5 MTHFR SERPINC1
18 hemolytic uremic syndrome, atypical 1 29.7 ADAMTS13 CD46 CFH CFI VWF
19 hemolytic-uremic syndrome 29.7 ADAMTS13 CD46 CFH CFI HP VWF
20 retinal vein occlusion 29.7 APOH F2 F5 MTHFR SERPINC1 SERPINE1
21 arteries, anomalies of 29.5 FLT1 PGF SERPINC1 SERPINE1 VWF
22 placental abruption 29.5 APOH F2 F5 FLT1 MTHFR PGF
23 pulmonary embolism 29.5 APOH F2 F5 MTHFR SERPINC1 SERPINE1
24 myocardial infarction 29.4 ADAMTS13 F2 F5 MTHFR PGF SERPINC1
25 catastrophic antiphospholipid syndrome 29.4 ADAMTS13 APOH CFH F5 MTHFR SERPINE1
26 preeclampsia/eclampsia 1 11.1
27 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 11.1
28 paracetamol poisoning 10.3 F2 F5
29 hepatoportal sclerosis 10.3 F2 GPT
30 paraquat poisoning 10.3 GPT SLC17A5
31 retinal detachment 10.3
32 arteritic anterior ischemic optic neuropathy 10.3 F2 F5 MTHFR
33 pyridoxine deficiency 10.3 GPT SLC17A5
34 mesenteric vascular occlusion 10.3 F2 MTHFR
35 porencephaly 10.3 F2 F5 MTHFR
36 kwashiorkor 10.3 F2 GPT SLC17A5
37 sagittal sinus thrombosis 10.3 F2 F5 SERPINC1
38 infantile liver failure syndrome 1 10.3 F2 GPT SLC17A5
39 leech infestation 10.3 F2 SERPINC1
40 gastroschisis 10.3 F2 F5 MTHFR
41 nonalcoholic steatohepatitis 10.3 F2 GPT SLC17A5
42 kidney cortex necrosis 10.3 GPT HADHA
43 intestinal impaction 10.3 F2 SERPINC1
44 thrombasthenia 10.3 F2 F5 MTHFR
45 choledocholithiasis 10.3 F2 GPT SLC17A5
46 marantic endocarditis 10.3 F2 MTHFR SERPINC1
47 hemorrhagic fever 10.3 F2 GPT SERPINC1
48 analbuminemia 10.3 F2 GPT SLC17A5
49 may-thurner syndrome 10.3 APOH F5
50 fournier gangrene 10.3 F2 SERPINC1

Graphical network of the top 20 diseases related to Hellp Syndrome:



Diseases related to Hellp Syndrome

Symptoms & Phenotypes for Hellp Syndrome

MGI Mouse Phenotypes related to Hellp Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 ADAMTS13 APOH CFH CFI F2 F5
2 cardiovascular system MP:0005385 10 CD46 CFH F2 F5 FLT1 HADHA
3 mortality/aging MP:0010768 9.77 ADAMTS13 APOH CFH F2 F5 FLT1
4 vision/eye MP:0005391 9.23 ADAMTS13 CD46 CFH FLT1 MTHFR PGF

Drugs & Therapeutics for Hellp Syndrome

Drugs for Hellp Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3 1177-87-3
3
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 7487-88-9 24083
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9 Hormones Phase 4,Phase 3,Not Applicable
10 Hormone Antagonists Phase 4,Phase 3,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
12 Calcium, Dietary Phase 4,Phase 3,Phase 2
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3
15 Anti-Inflammatory Agents Phase 4,Phase 3
16 Antiemetics Phase 4,Phase 3
17 glucocorticoids Phase 4,Phase 3
18 HIV Protease Inhibitors Phase 4,Phase 3
19
protease inhibitors Phase 4,Phase 3
20 BB 1101 Phase 4,Phase 3
21 Autonomic Agents Phase 4,Phase 3,Phase 2
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
23 Follicle Stimulating Hormone Phase 4
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
25 calcium channel blockers Phase 4,Phase 2,Phase 3
26 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
27 Tocolytic Agents Phase 4,Phase 2,Phase 3
28 Anticonvulsants Phase 4,Phase 2,Phase 3
29 Analgesics Phase 4,Phase 3,Phase 2
30 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
31 Vitamins Phase 4,Phase 3
32 Micronutrients Phase 4,Phase 3
33 Bone Density Conservation Agents Phase 4,Phase 3
34 Trace Elements Phase 4,Phase 3
35 Pharmaceutical Solutions Phase 4,Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
37 Cyclooxygenase Inhibitors Phase 4,Phase 3
38 Antirheumatic Agents Phase 4,Phase 3
39 Analgesics, Non-Narcotic Phase 4,Phase 3
40 Antipyretics Phase 4,Phase 3
41 Calciferol Phase 4
42 Vitamin D2 Phase 4
43 Ergocalciferols Phase 4
44
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
45
Dalteparin Approved Phase 3 9005-49-6
46
Enoxaparin Approved Phase 3 9005-49-6 772
47
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
48
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
49
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
50
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 119141-88-7 4594 9579578

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
2 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
3 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
4 Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome Active, not recruiting NCT00711841 Phase 4 dexamethasone;Placebo;dexamethasone
5 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
6 Dexamethasone Efficacy in HELLP I Syndrome Unknown status NCT01138839 Phase 3 Dexamethasone;sterile water
7 A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Unknown status NCT02336243 Phase 3
8 Calcium for Pre-Eclampsia Prevention (CPEP) Completed NCT00000534 Phase 3 calcium
9 RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil Completed NCT00097110 Phase 3 Vitamin C and E
10 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
11 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) Completed NCT00135707 Phase 3 Dietary Supplement/Vitamins;Placebo for Vitamin C and Vitamin E
12 Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial) Recruiting NCT03213639 Phase 2, Phase 3 Esomeprazole 40 mg Oral Tablet;Placebo Oral Tablet
13 Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes Recruiting NCT03377699 Phase 3 Insulin degludec;Insulin Aspart;Insulin detemir
14 Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide Recruiting NCT03298802 Phase 3 Hydrochlorothiazide 50mg Tablet;Placebo Tablet
15 Pregnancy Outcomes: Effects of Metformin Study (POEM Study) Not yet recruiting NCT02947503 Phase 3 Metformin HCL 850 CF
16 The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction) Terminated NCT02277132 Phase 2, Phase 3 Sildenafil;Placebo
17 Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
18 Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
19 ToRsemide for pOstpartum HYpertension Completed NCT02813551 Phase 2 Torsemide;Placebo
20 Indonesia Pravastatin to Prevent Preeclampsia Study Recruiting NCT03648970 Phase 2 Pravastatin
21 Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia Terminated NCT02286284 Phase 2
22 The SMART-ORACLE Study Unknown status NCT01932671
23 Hypertensive Disorders of Pregnancy in Adolescence and Primipaternity Unknown status NCT01374477
24 A Lifestyle Intervention to Improve in Vitro Fertilization Results Unknown status NCT02648555 Not Applicable
25 Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) Unknown status NCT01431352 Not Applicable Letrozole;Chinese herbal medicine granules or Chinese herbal medicine granules placebo
26 General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome Completed NCT03111446 Not Applicable
27 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
28 Correlation of Survival in Puerperae by Electrical Impedance Tomography Completed NCT03715647
29 Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome Completed NCT03232359
30 Platelet Count Trends in Pre-eclamptic Parturients Completed NCT00787241
31 A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk Completed NCT00572793
32 Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia Completed NCT03412552 MgSO4
33 Serum Cobalt Status During Pregnancy and the Risks of PIH Completed NCT03215368
34 Free DNA and Nucleosome Concentrations in Pathological Pregnancies Completed NCT01736826
35 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. Completed NCT02757950
36 Doppler and Biological Second Trimester Placental Insufficiency Screening Completed NCT00465634
37 Study of Coagulation Activation Markers and Pre Eclampsia Completed NCT01261351
38 Early Placental Insufficiency Screening Completed NCT01348711
39 Endometriosis and Risk of Obstetric Complications Completed NCT03354793
40 Retrospective Longitudinal Study of Gestational Weight Gain Among Chinese Pregnant Women Completed NCT03154268
41 Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies Completed NCT02623881 Not Applicable Vaginal progesterone
42 Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF) Completed NCT02471573 Not Applicable
43 Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome Recruiting NCT02754778 Not Applicable
44 The Preeclampsia Registry Recruiting NCT02020174
45 Women Specific Cardiac Recovery After Preeclampsia Recruiting NCT02807324
46 Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy. Recruiting NCT03455387
47 Pancreatic Stone Protein (PSP) in Pregnant Women Recruiting NCT02247297
48 Serum Immunologic Markers Levels in During the Delivery Recruiting NCT03664999
49 PC Protocol: Preconceptional Screening Recruiting NCT02309073
50 Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia Recruiting NCT02373839 Not Applicable

Search NIH Clinical Center for Hellp Syndrome

Cochrane evidence based reviews: hellp syndrome

Genetic Tests for Hellp Syndrome

Anatomical Context for Hellp Syndrome

MalaCards organs/tissues related to Hellp Syndrome:

41
Liver, Kidney, Testes, Brain, Bone, Spinal Cord, Myeloid

Publications for Hellp Syndrome

Articles related to Hellp Syndrome:

(show top 50) (show all 742)
# Title Authors Year
1
Hepatic infarction induced by HELLP syndrome: a case report and review of the literature. ( 29848304 )
2018
2
Dexamethasone in HELLP syndrome: experience in Bolivia. ( 29804488 )
2018
3
Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. ( 29563339 )
2018
4
Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome. ( 29321548 )
2018
5
HELLP syndrome, risk factors in first and second pregnancy: a population-based cohort study. ( 29430625 )
2018
6
Risk of eclampsia or HELLP-syndrome by institution availability and place of delivery - A population-based cohort study. ( 30527094 )
2018
7
FAS A-670G and Fas ligand IVS2nt A 124G polymorphisms are significantly increased in women with pre-eclampsia and may contribute to HELLP syndrome: a case-controlled study. ( 30066360 )
2018
8
Central PRES (posterior reversible encephalopathy syndrome) in HELLP syndrome. ( 30519918 )
2018
9
HELLP Syndrome: Pathophysiology and Current Therapies. ( 29998801 )
2018
10
Attenuation of oxidative stress and hypertension in an animal model of HELLP syndrome. ( 30012496 )
2018
11
Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. ( 30046254 )
2018
12
Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome. ( 30129291 )
2018
13
Markedly higher sFlt-1/PlGF ratio in a woman with acute fatty liver of pregnancy compared with HELLP syndrome. ( 30141235 )
2018
14
Postpartal Pelvic Hemorrhage in a Patient with Hellp Syndrome Treated with Hemostatic Sponge. ( 30142689 )
2018
15
Plasmapheresis-A lifesaving treatment for life threatening HELLP syndrome. ( 30217368 )
2018
16
Elastic properties of ascending aorta and ventricular-arterial coupling in women with previous pregnancy complicated by HELLP syndrome. ( 30234780 )
2018
17
Preterm Labor Caused by Hemolysis, Elevated Liver Enzymes, Low Platelet Count (HELLP) Syndrome and Postpartum Infection Complicated with Actinomyces Species: A Case Report. ( 30420589 )
2018
18
HELLP Syndrome Complicated By Pulmonary Edema: A Case Report. ( 30426089 )
2018
19
Color vision abnormality as the sole manifestation of posterior reversible encephalopathy due to post-partum HELLP syndrome. ( 28109137 )
2017
20
Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome. ( 28501275 )
2017
21
Massive Hepatic Infarction Caused by HELLP Syndrome. ( 28670595 )
2017
22
Importance of correctly interpreting magnetic resonance imaging to diagnose posterior reversible encephalopathy syndrome associated with HELLP syndrome: a case report. ( 28545408 )
2017
23
Maternal cardiac function after HELLP syndrome: an echocardiography study. ( 28971558 )
2017
24
Pravastatin for prevention of HELLP syndrome: A case report. ( 29049209 )
2017
25
Conservative versus active management in HELLP syndrome: results from a cohort study. ( 29228827 )
2017
26
A Case of Postpartum HELLP Syndrome. ( 29465852 )
2017
27
SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY EVALUATION OF CHORIORETINAL CHANGES IN HYPERTENSIVE CHOROIDOPATHY RELATED TO HELLP SYNDROME. ( 28067720 )
2017
28
HELLP syndrome in a pregnant patient with Gitelman syndrome. ( 28393002 )
2017
29
Haemophagocytic lymphohistiocytosis presenting as HELLP syndrome: a diagnostic and therapeutic challenge. ( 28433984 )
2017
30
A Case Report of the Nutrition Support for a Patient with HELLP Syndrome. ( 28503510 )
2017
31
Description of a strong relationship among total cell-free DNA levels, LDH values, AST values and platelet count in patients with HELLP syndrome. ( 28331215 )
2017
32
Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. ( 28338787 )
2017
33
Intensive Care Unit issues in eclampsia and HELLP syndrome. ( 28971026 )
2017
34
Diagnosis and Management of HELLP Syndrome Complicated by Liver Hematoma. ( 28005587 )
2017
35
Hematoma After Transversus Abdominis Plane Block in a Patient With HELLP Syndrome: A Case Report. ( 28252541 )
2017
36
Factors contributing to adverse maternal outcomes in patients with HELLP syndrome. ( 28784005 )
2017
37
Recurrent HELLP Syndrome at 22 Weeks of Gestation. ( 28929001 )
2017
38
Microcirculatory blood flow derangements during severe preeclampsia and HELLP syndrome. ( 29153664 )
2017
39
Maternal bradycardia occurring prior to onset of HELLP syndrome in a woman with pre-eclampsia. ( 28501825 )
2017
40
Life-threatening bleeding from gastric dieulafoy's lesion in a pregnant woman with hellp syndrome: a case report and literature review. ( 28760134 )
2017
41
Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome. ( 29296808 )
2017
42
Transfusion Related Acute Lung Injury after Cesarean Section in a Patient with HELLP Syndrome. ( 26885326 )
2016
43
Scrub typhus masquerading as HELLP syndrome and puerperal sepsis in an asymptomatic malaria patient. ( 27413718 )
2016
44
Hepatic Artery Embolization for Hepatic Rupture in HELLP Syndrome. ( 27886958 )
2016
45
Resolution of HELLP syndrome after selective feticide for trisomy 21 in discordant twins - A case report. ( 26804722 )
2016
46
HELLP Syndrome: Altered Hypoxic Response of the Fatty Acid Oxidation Regulator SIRT 4. ( 27651178 )
2016
47
CHOROIDAL MORPHOLOGY IN A PATIENT WITH HELLP SYNDROME. ( 26595148 )
2016
48
Are there any additional mechanisms for haemolysis in HELLP syndrome? ( 27128171 )
2016
49
A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. ( 27028698 )
2016
50
Maternal endothelial function and vascular stiffness after HELLP syndrome: a case-control study. ( 28004456 )
2016

Variations for Hellp Syndrome

Expression for Hellp Syndrome

Search GEO for disease gene expression data for Hellp Syndrome.

Pathways for Hellp Syndrome

GO Terms for Hellp Syndrome

Cellular components related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.9 APOH CD46 CFH CFI F2 GPT
2 extracellular region GO:0005576 9.77 ADAMTS13 APOH CFH CFI F2 F5
3 endoplasmic reticulum lumen GO:0005788 9.73 ADAMTS13 F2 F5 SERPINC1
4 collagen-containing extracellular matrix GO:0062023 9.67 APOH SERPINC1 SERPINE1 VWF
5 blood microparticle GO:0072562 9.56 CFH F2 HP SERPINC1
6 platelet alpha granule lumen GO:0031093 9.5 F5 SERPINE1 VWF
7 extracellular space GO:0005615 9.44 ADAMTS13 APOH CFH CFI F2 F5
8 platelet alpha granule GO:0031091 9.4 F5 VWF

Biological processes related to Hellp Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.77 ADAMTS13 F2 F5 SERPINC1 VWF
2 platelet degranulation GO:0002576 9.73 APOH F5 SERPINE1 VWF
3 regulation of complement activation GO:0030449 9.71 CD46 CFH CFI F2
4 platelet activation GO:0030168 9.67 ADAMTS13 F2 VWF
5 blood coagulation, intrinsic pathway GO:0007597 9.5 APOH F2 VWF
6 vascular endothelial growth factor signaling pathway GO:0038084 9.48 FLT1 PGF
7 negative regulation of blood coagulation GO:0030195 9.46 APOH SERPINE1
8 positive regulation of blood coagulation GO:0030194 9.43 APOH F2 SERPINE1
9 regulation of blood coagulation GO:0030193 9.33 APOH F2 SERPINC1
10 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
11 hemostasis GO:0007599 9.02 ADAMTS13 F2 F5 SERPINC1 VWF

Molecular functions related to Hellp Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.13 SERPINC1 SERPINE1 VWF
2 heparin binding GO:0008201 9.02 APOH CFH F2 PGF SERPINC1

Sources for Hellp Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....